{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:14:19Z","timestamp":1784589259904,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T00:00:00Z","timestamp":1390262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T00:00:00Z","timestamp":1390262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/leu.2014.32","type":"journal-article","created":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T07:42:31Z","timestamp":1390290151000},"page":"1501-1510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The CD37-targeted antibody\u2013drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model"],"prefix":"10.1038","volume":"28","author":[{"given":"K A","family":"Beckwith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F W","family":"Frissora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Stefanovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W H","family":"Towns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Cheney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Deckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L A","family":"Andritsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K J","family":"Maddocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Lozanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Muthusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,21]]},"reference":[{"key":"BFleu201432_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","volume":"105","author":"JC Byrd","year":"2005","unstructured":"Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49\u201353.","journal-title":"Blood"},{"key":"BFleu201432_CR2","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","volume":"117","author":"XC Badoux","year":"2011","unstructured":"Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117: 3016\u20133024.","journal-title":"Blood"},{"key":"BFleu201432_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","volume":"63","author":"GL Plosker","year":"2003","unstructured":"Plosker GL, Figgitt DP . Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803\u2013843.","journal-title":"Drugs"},{"key":"BFleu201432_CR4","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","volume":"29","author":"JA Woyach","year":"2011","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011; 29: 1349\u20131355.","journal-title":"J Clin Oncol"},{"key":"BFleu201432_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","volume":"24","author":"AR Rezvani","year":"2011","unstructured":"Rezvani AR, Maloney DG . Rituximab resistance. Best Pract Res Clin Haematol 2011; 24: 203\u2013216.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu201432_CR6","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.4049\/jimmunol.137.9.3013","volume":"137","author":"MP Link","year":"1986","unstructured":"Link MP, Bindl J, Meeker TC, Carswell C, Doss CA, Warnke RA et al. A unique antigen on mature B-cells defined by a monoclonal antibody. J Immunol 1986; 137: 3013\u20133018.","journal-title":"J Immunol"},{"key":"BFleu201432_CR7","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4049\/jimmunol.140.3.905","volume":"140","author":"R Schwartz-Albiez","year":"1988","unstructured":"Schwartz-Albiez R, Dorken B, Hofmann W, Moldenhauer G . The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 1988; 140: 905\u2013914.","journal-title":"J Immunol"},{"key":"BFleu201432_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","volume":"21","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012; 21: 694\u2013708.","journal-title":"Cancer Cell"},{"key":"BFleu201432_CR9","doi-asserted-by":"publisher","first-page":"ra82","DOI":"10.1126\/scisignal.2003113","volume":"5","author":"AB van Spriel","year":"2012","unstructured":"van Spriel AB, de Keijzer S, van der Schaaf A, Gartlan KH, Sofi M, Light A et al. The tetraspanin CD37 orchestrates the alpha(4)beta(1) integrin-Akt signaling axis and supports long-lived plasma cell survival. Sci Signal 2012; 5: ra82.","journal-title":"Sci Signal"},{"key":"BFleu201432_CR10","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","volume":"110","author":"X Zhao","year":"2007","unstructured":"Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007; 110: 2569\u20132577.","journal-title":"Blood"},{"key":"BFleu201432_CR11","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1182\/blood-2011-04-351932","volume":"118","author":"KH Heider","year":"2011","unstructured":"Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 2011; 118: 4159\u20134168.","journal-title":"Blood"},{"key":"BFleu201432_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/leu.2011.233","volume":"26","author":"G Krause","year":"2012","unstructured":"Krause G, Patz M, Isaeva P, Wigger M, Baki I, Vondey V et al. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 2012; 26: 546\u2013549.","journal-title":"Leukemia"},{"key":"BFleu201432_CR13","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","volume":"122","author":"J Deckert","year":"2013","unstructured":"Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 2013; 122: 3500\u20133510.","journal-title":"Blood"},{"key":"BFleu201432_CR14","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1158\/1535-7163.MCT-10-0645","volume":"9","author":"E Oroudjev","year":"2010","unstructured":"Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 2010; 9: 2700\u20132713.","journal-title":"Mol Cancer Ther"},{"key":"BFleu201432_CR15","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783\u20131791.","journal-title":"N Engl J Med"},{"key":"BFleu201432_CR16","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","volume":"18","author":"RA de Claro","year":"2012","unstructured":"de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012; 18: 5845\u20135849.","journal-title":"Clin Cancer Res"},{"key":"BFleu201432_CR17","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1172\/JCI23409","volume":"115","author":"BT Messmer","year":"2005","unstructured":"Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B-cells. J Clin Invest 2005; 115: 755\u2013764.","journal-title":"J Clin Invest"},{"key":"BFleu201432_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.beha.2007.03.007","volume":"20","author":"N Chiorazzi","year":"2007","unstructured":"Chiorazzi N . Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B-cells. Best Pract Res Clin Haematol 2007; 20: 399\u2013413.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu201432_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1046\/j.1365-2141.2003.04679.x","volume":"123","author":"F Caligaris-Cappio","year":"2003","unstructured":"Caligaris-Cappio F . Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003; 123: 380\u2013388.","journal-title":"Br J Haematol"},{"key":"BFleu201432_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.humpath.2005.09.029","volume":"37","author":"LA Soma","year":"2006","unstructured":"Soma LA, Craig FE, Swerdlow SH . The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia\/small lymphocytic lymphoma. Hum Pathol 2006; 37: 152\u2013159.","journal-title":"Hum Pathol"},{"key":"BFleu201432_CR21","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1200\/JCO.2007.15.4393","volume":"26","author":"F Caligaris-Cappio","year":"2008","unstructured":"Caligaris-Cappio F, Ghia P . Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008; 26: 4497\u20134503.","journal-title":"J Clin Oncol"},{"key":"BFleu201432_CR22","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/leu.2011.14","volume":"25","author":"ML Vandewoestyne","year":"2011","unstructured":"Vandewoestyne ML, Pede VC, Lambein KY, Dhaenens MF, Offner FC, Praet MM et al. Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia\/small lymphocytic lymphoma and proliferating B-cells within lymph node pseudofollicles. Leukemia 2011; 25: 883\u2013888.","journal-title":"Leukemia"},{"key":"BFleu201432_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajh.21406","volume":"84","author":"A Broyde","year":"2009","unstructured":"Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O . Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol 2009; 84: 338\u2013343.","journal-title":"Am J Hematol"},{"key":"BFleu201432_CR24","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.4049\/jimmunol.176.4.2208","volume":"176","author":"HC Chen","year":"2006","unstructured":"Chen HC, Byrd JC, Muthusamy N . Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival. J Immunol 2006; 176: 2208\u20132218.","journal-title":"J Immunol"},{"key":"BFleu201432_CR25","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1073\/pnas.102181599","volume":"99","author":"R Bichi","year":"2002","unstructured":"Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955\u20136960.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201432_CR26","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","volume":"108","author":"AJ Johnson","year":"2006","unstructured":"Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108: 1334\u20131338.","journal-title":"Blood"},{"key":"BFleu201432_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/cyto.a.10030","volume":"52","author":"Y Vugmeyster","year":"2003","unstructured":"Vugmeyster Y, Howell K, Bakshl A, Flores C, Canova-Davis E . Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B-cells in a whole blood matrix. Cytometry A 2003; 52: 101\u2013109.","journal-title":"Cytometry A"},{"key":"BFleu201432_CR28","doi-asserted-by":"publisher","first-page":"11713","DOI":"10.1073\/pnas.0604564103","volume":"103","author":"XJ Yan","year":"2006","unstructured":"Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103: 11713\u201311718.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201432_CR29","first-page":"2427","volume":"118","author":"AG Ramsay","year":"2008","unstructured":"Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118: 2427\u20132437.","journal-title":"J Clin Invest"},{"key":"BFleu201432_CR30","doi-asserted-by":"publisher","first-page":"13433","DOI":"10.1073\/pnas.0906455106","volume":"106","author":"SS Chen","year":"2009","unstructured":"Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2009; 106: 13433\u201313438.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201432_CR31","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.2174\/138161208785294591","volume":"14","author":"P Macor","year":"2008","unstructured":"Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C, Tedesco F . An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des 2008; 14: 2023\u20132039.","journal-title":"Curr Pharm Des"},{"key":"BFleu201432_CR32","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1182\/blood.V89.6.2210","volume":"89","author":"A Shimoni","year":"1997","unstructured":"Shimoni A, Marcus H, Canaan A, Ergas D, David M, Berrebi A et al. A model for human B-chronic lymphocytic leukemia in human\/mouse radiation chimera: evidence for tumor-mediated suppression of antibody production in low-stage disease. Blood 1997; 89: 2210\u20132218.","journal-title":"Blood"},{"key":"BFleu201432_CR33","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1158\/0008-5472.CAN-07-1198","volume":"67","author":"J Durig","year":"2007","unstructured":"Durig J, Ebeling P, Grabellus F, Sorg UR, Mollmann M, Schutt P et al. A novel nonobese diabetic\/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007; 67: 8653\u20138661.","journal-title":"Cancer Res"},{"key":"BFleu201432_CR34","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","volume":"19","author":"S Barrena","year":"2005","unstructured":"Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 2005; 19: 1376\u20131383.","journal-title":"Leukemia"},{"key":"BFleu201432_CR35","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1182\/blood-2008-09-175430","volume":"113","author":"DM Lucas","year":"2009","unstructured":"Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009; 113: 4656\u20134666.","journal-title":"Blood"},{"key":"BFleu201432_CR36","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","volume":"120","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y et al. Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012; 120: 4621\u20134634.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201432.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201432","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201432.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T23:04:18Z","timestamp":1688943858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,21]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["BFleu201432"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.32","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,21]]},"assertion":[{"value":"12 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JD is an employee of ImmunoGen Inc. All the remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}